Forecast horizon — calibration-scored at resolution.
By 2028, neoadjuvant checkpoint inhibition will be standard-of-care for stage II–III TNBC across major oncology guidelines.
Your probability this resolves TRUE
0% (impossible)
50%
100% (certain)
Proper-scoring-rule preview
Your position is kept on this device until you sign in.
Evidence stream
2 events · 1 snapshot
posterior drift
71% → 71% (0pp · 1 point)
Registry data
Apr 18, 2026
Peer-reviewed paper
Apr 18, 2026
Expert reactions · 0
Sign in to post a take, cite a related claim, or flag a methodological concern.
No reactions yet. Be the first expert to post a take, cite a related claim, or flag a methodological concern.
Source publication
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al. · New England Journal of Medicine · 2020
· openalex W3006930853
Semantically related
Nearest claims in the expert-corpus vector space. Ordered by cosine distance — lower is closer.
0.1866
The KEYNOTE-522 trial's stated primary conclusion — Neoadjuvant pembrolizumab + chemotherapy increases pathologic complete response rate in triple-negative breast cancer. — replicates in independent cohorts.
0.2013
By 2028, pembrolizumab-containing regimens will be first-line for >90% of eligible metastatic non-squamous NSCLC in US practice.
0.2363
By 2028, antibody-drug conjugates (T-DXd class) will have largely displaced T-DM1 as second-line HER2+ metastatic therapy.
0.2444
By 2028, 10-year survival data from CheckMate-067 will show a plateau ≥40% in the combination arm.
0.2504
Durvalumab consolidation after chemoradiotherapy will demonstrate a statistically significant overall survival benefit in the final analysis of the PACIFIC trial in stage III unresectable NSCLC.
0.2590
By 2028, sham-controlled trials (ORBITA-2 and successors) will define reimbursement criteria for elective PCI in stable CAD.